Abstract

 While metformin is the treatment of choice for most children and adolescents with type 2 diabetes, along with lifestyle interventions such as diet and exercise, approximately half of youth with type 2 diabetes fail to maintain glycemic control when treated with metformin, either alone or in conjunction with lifestyle interventions.
 Basal insulin can be used in children and adolescents with type 2 diabetes who do not have an adequate response to metformin monotherapy; however, basal insulin therapy has been associated with weight gain and hypoglycemia.
 There is very limited evidence of moderate to moderately high-quality to support the effectiveness of liraglutide (Victoza) in attaining glycemic control when added to treatment with metformin, with or without basal insulin, in children and adolescents with type 2 diabetes.
 Adverse events, such as hypoglycemia and gastrointestinal issues, are reportedly higher in patients receiving liraglutide (Victoza) than in those receiving placebo.
 There is a lack of long-term safety data evaluating the use of liraglutide (Victoza) in children and adolescents with type 2 diabetes.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
